Overview
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Description
Evaluation of Efficacy, Safety and Tolerability of NGM120 in a Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Participants with Colorectal Cancer who have Cancer Cachexia
Eligibility
Inclusion Criteria:
- Documented active diagnosis of colorectal cancer.
- Cachexia defined by Fearon criteria of weight loss.
- Signed informed consent.
Exclusion Criteria:
- Current active reversible causes of decreased food intake.
- Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
- Have cachexia caused by other reasons.